According to the Zhitong Finance App, Weijun Biotechnology (00660) announced results for the six months ended December 31, 2023. The group achieved revenue of HK$190 million during the period, a decrease of 53.01% year on year; loss due to company owners during the period was HK$6.734 million, a decrease of 14.01% year on year; basic loss per share was HK$3.93.
According to the announcement, the decline in revenue was due to a decrease in market consumption and demand during the period.